Astrocyte Pharmaceuticals
Astrocyte Pharmaceuticals: Innovating neuroprotective strategies through small molecule medicines.
Founded
2014Astrocyte Pharmaceuticals: Innovating neuroprotective strategies through small molecule medicines.
Astrocyte Pharmaceuticals was founded with the core mission of developing innovative neuroprotective strategies to protect and repair neurons by selectively stimulating astrocytes. The company focuses on creating small molecule pharmaceutical medicines aimed at providing neuroprotection for a range of brain injuries, including traumatic brain injuries (TBI), concussions, strokes, and neurodegenerative diseases. Their market focus is on advancing these treatments to improve outcomes for patients suffering from these debilitating conditions.
Notable affiliated individuals include experts in neuroscience and pharmaceutical development, though specific names are not provided. Key achievements include the successful advancement of their neuroprotective small molecule medicines through various stages of research and development. The overall impact of Astrocyte Pharmaceuticals lies in their potential to significantly improve the quality of life for patients with brain injuries and neurodegenerative diseases by reducing damage and promoting healing through innovative treatments.
Companies similar to Astrocyte Pharmaceuticals include NeurAegis, Zocere, Alcyone Lifesciences and NeuExcell Therapeutics.
Astrocyte Pharmaceuticals was founded in 2014.
Astrocyte Pharmaceuticals' headquarters is located in Groton, CT, US.
Astrocyte Pharmaceuticals' most recent funding round was for $6M (USD) in August 2023.
As of Aug 18, 2023, Astrocyte Pharmaceuticals has disclosed funding of $31.9M (USD). Undisclosed round amounts are excluded.
Astrocyte Pharmaceuticals has 30 employees as of Feb 5, 2024.
NeuExcell Therapeutics
neuexcell.com
